Home › Funds › Boston Common Asset Management, LLC › VRTX

Boston Common Asset Management, LLC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Boston Common Asset Management, LLC reported holding 23,215 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$12.1M, representing 0.71% of its reported portfolio and ranking #46 among its reported holdings. Boston Common Asset Management, LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)23.21K sh
Reported value held$12.14M
Portfolio Weight0.71%
First reportedQ3 2023
Last changeAdd
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How Boston Common Asset Management, LLC's VRTX position evolved

Boston Common Asset Management, LLC first disclosed a stake in VRTX in Q3 2023 at 58,027 shares (US$20.2M). The position peaked in Q1 2025 at 50,963 shares, worth US$24.7M. Across 13 filings, Boston Common Asset Management, LLC increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 23,215 shares valued at US$12.1M — an increase of 3,722 shares quarter over quarter.. Notable position changes include a 29% trim in Q1 2024 (shares rose 12% over the following quarter), a 35% increase in Q3 2024 (shares fell 13% over the following quarter), a 61% trim in Q4 2025 (shares fell 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 58.03K $20.18M New
Q4 2023 55.36K $22.52M Reduce
Q1 2024 39.32K $16.44M Reduce
Q2 2024 37.26K $17.46M Reduce
Q3 2024 50.27K $23.38M Add
Q4 2024 50.29K $20.25M Hold
Q1 2025 50.96K $24.71M Add
Q2 2025 46.06K $20.51M Reduce
Q3 2025 40.90K $16.02M Reduce
Q4 2025 16.08K $7.29M Reduce
Q1 2026 17.20K $7.68M Add
Q2 2026 19.49K $9.68M Add
Q3 2026 23.21K $12.14M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Boston Common Asset Management, LLC held VRTX?

Boston Common Asset Management, LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Boston Common Asset Management, LLC's current position in VRTX?

As of Q3 2026, Boston Common Asset Management, LLC holds 23.21K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $12.14M, representing 0.71% of its reported portfolio and ranking #46.

Has Boston Common Asset Management, LLC been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Boston Common Asset Management, LLC increased its position in VRTX. The position peaked in Q1 2025 at 50.96K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.